Literature DB >> 10755649

55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study.

P Goethals1, A Volkaert, C Vandewielle, R Dierckx, N Lameire.   

Abstract

The feasibility of imaging renal function with 55Co-ethylene diamine tetraacetic acid (EDTA) and dynamic positron emission tomography was investigated. A group of normal Wistar rats was injected intravenously with 55Co-EDTA and underwent dynamic positron emission tomography (PET) imaging in order to study the biodistribution. The time-activity curves of the heart (blood pool), both kidneys, liver, and bladder were observed. In two animals, blood and urinary clearances of 55Co-EDTA were compared with those for 51Cr-EDTA. In one animal, unilateral reduction in kidney function was induced and the right/left ratio for the kidneys was determined. The time-activity curves showed that 55Co-EDTA cleared rapidly from the blood pool (heart), whereas prompt and high target-to-background ratios for both kidneys were obtained. The entire tracer was cleared from the renal parenchyma by urinary excretion and collection of the activity in the bladder. No specific activity uptake was noticed in any other organ or tissue. The clearances of 55Co-EDTA and 51Cr-EDTA in blood were not significantly different, showing that the nature of the M++ has no influence on the in vivo behavior of EDTA. 55Co can be produced easily by cyclotron irradiation and 55Co-EDTA is a promising physiological tracer for nephrological research using PET.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755649     DOI: 10.1016/s0969-8051(99)00077-3

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide Complexes.

Authors:  Tara Mastren; Bernadette V Marquez; Deborah E Sultan; Elizabeth Bollinger; Paul Eisenbeis; Tom Voller; Suzanne E Lapi
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

Review 2.  Mapping biological behaviors by application of longer-lived positron emitting radionuclides.

Authors:  Yang Zhou; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

3.  Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Authors:  H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2017-09-06       Impact factor: 1.513

4.  Future direction of renal positron emission tomography.

Authors:  Zsolt Szabo; Jinsong Xia; William B Mathews; Phillip R Brown
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

Review 5.  Unconventional nuclides for radiopharmaceuticals.

Authors:  Jason P Holland; Matthew J Williamson; Jason S Lewis
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

Review 6.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

7.  Assessing Glomerular Filtration in Small Animals Using [68Ga]DTPA and [68Ga]EDTA with PET Imaging.

Authors:  Daniel Gündel; Ulrike Pohle; Erik Prell; Andreas Odparlik; Oliver Thews
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 8.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

Review 9.  PET radiometals for antibody labeling.

Authors:  Eduardo Aluicio-Sarduy; Paul A Ellison; Todd E Barnhart; Weibo Cai; Robert Jerry Nickles; Jonathan W Engle
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

10.  Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors.

Authors:  Helena Wållberg; Sara Ahlgren; Charles Widström; Anna Orlova
Journal:  Mol Imaging Biol       Date:  2009-06-26       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.